All In Biotech

Drug Trial Radar · NCT02205762

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,400 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,400

Actual

Start

Nov 2, 2016

Primary completion

Nov 2031

Study completion Nov 2031

Sponsor

Lead sponsor
North American Consortium for HistiocytosisAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Histiocyte Society
First posted
Jul 31, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age \< 18 years).

Conditions

  • Langerhans Cell Histiocytosis

Interventions

  • PrednisoneDrug

    Stratum I

  • VinblastineDrug

    Stratum I

  • mercaptopurineDrug

    Stratum I

  • INDOMETHACINDrug

    Indomethacin fixed dose given daily orally in two divided doses with gastric protection for total treatment duration of 24 months.

  • MethotrexateDrug

    fixed dose weekly orally for total treatment duration of 24 months.

  • Cytosine ArabinosideDrug

  • 2-chlorodeoxyadenosineDrug

  • hematopoietic stem cell transplantation (RIC-HSCT)Procedure

  • Intravenous immunoglobulinBiological

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients with Reactivation Free SurvivalTime frame: 12 Months
  2. Response Rate of Second CycleTime frame: 9 weeks
  3. Overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT)Time frame: 3 Years
  4. The cumulative incidence of radiological and clinical neurodegeneration in patients with isolated tumorous CNS-LCH, DI, anterior pituitary dysfunction, and those with CNS-risk lesionsTime frame: 2 Years
  5. The time interval and cumulative incidence of progression of radiological neurodegeneration to clinically manifested ND-CNS-LCHTime frame: 2 Years
  6. Cumulative incidence of specific Permanent Consequences e.g. diabetes insipidus (DI), growth hormone deficiency (GHD), neuropsychological impairment, etc.Time frame: 2 Years

Locations

42 sites in 1 country. Site status is shown where the registry gives one.

  • Children's of Alabama

    Birmingham, Alabama

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • Children's Hospital of Los Angeles

    Los Angeles, California

  • Valley Children's Healthcare

    Madera, California

  • UCSF Benioff Children's Hospital of Oakland

    Oakland, California

  • Children's Hospital of Orange County

    Orange, California

  • UCSF Helen Diller Family Cancer Center

    San Francisco, California

  • Connecticut Children's Medical Center

    Hartford, Connecticut

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Johns Hopkins All Children's Hospital

    St. Petersburg, Florida

  • Children's Healthcare of Atlanta, Emory

    Atlanta, Georgia

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Riley Hospital for Children - Indiana University

    Indianapolis, Indiana

  • Children's Mercy Hospitals

    Kansas City, Kansas

  • University of Kentucky A.B.Chandler Medical Center

    Lexington, Kentucky

  • University of Louisville, Norton Children's Hospital

    Louisville, Kentucky

  • Johns Hopkins University

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Children's Minnesota

    Minneapolis, Minnesota

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Cohen Children's Medical Center

    New Hyde Park, New York

  • Mount Sinai Hospital

    New York, New York

  • Columbia University / Herbert Irving Cancer Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • SUNY Upstate Medical University

    Syracuse, New York

  • Children's Hospital at Montefiore

    The Bronx, New York

  • Carolinas Medical Center, Levine Children's Hospital

    Charlotte, North Carolina

  • Akron Children's Hospital

    Akron, Ohio

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Rainbow Babies & Children's Hospital, University Hospitals

    Cleveland, Ohio

  • Russell J Ebeid Children's Hospital (Promedica)

    Toledo, Ohio

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina (MUSC)

    Charleston, South Carolina

  • Greenville Health System BI-LO Charities Children's Cancer Center

    Greenville, South Carolina

  • St. Jude Children's Research Hospital

    Memphis, Tennessee

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

  • Children's Medical Center Dallas, UT Southwestern

    Dallas, Texas

  • Providence Sacred Heart Children's Hospital

    Spokane, Washington

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.